Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, 7SL, cytoplasmic 712, pseudogene (abbreviated RN7SL712P), is a human pseudogene derived from the 7SL RNA, which is itself part of the signal recognition particle (SRP) involved in protein targeting to the endoplasmic reticulum[1][5][6][7]. RN7SL712P represents a truncated, non-functional copy of the original 7SL RNA gene and does not code for a functional RNA molecule or protein. The human genome contains numerous such 7SL pseudogenes, created via reverse transcription and genomic integration of 7SL RNA[5][6][7]. These pseudogenes are not expressed at detectable levels and do not possess established biological function, disease associations, or roles as therapeutic targets in current scientific knowledge[5][6][7]. Context and Clarification: - RN7SL712P is not a therapeutic target; it is a non-functional pseudogene and does not encode a receptor, enzyme, transporter, or any protein with a recognized biochemical or pharmacological role[1][5][6][7]. - There is nothing inherently misspelled or ambiguous about the name, but its status as a pseudogene (rather than functional gene or therapeutic target) warrants flagging as "is_incorrect: true" if the context expects a targetable molecule[1][5][6][7]. - No known biological functions, disease roles, or associated biomarkers are attributed to this pseudogene. This distinguishes it from the functional 7SL RNA (RN7SL1), which is a key component of the signal recognition particle complex[3][4], but RN7SL712P itself has no such function. If structured information is required for functional 7SL RNA or the SRP complex instead, please specify or re-query for "RN7SL1" or "Signal recognition particle RNA."
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, 7SL, cytoplasmic 712, pseudogene (RN7SL712P).